Related Experiment Video
Updated: Jan 17, 2026
08:37
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
17.4K
N6-methyladenosine regulators in inflammatory bowel disease
Yao Xiao1, Lijing Zhu2, Ran Yu2
1Department of Clinical Laboratory, Lianshui People's Hospital, Kangda College of Nanjing Medical University, Huai'an, Jiangsu, 223400, China; Jiangsu College of Nursing, Huai'an, Jiangsu, 223400, China.
Biochemical and Biophysical Research Communications
|September 19, 2025
Summary
N6-methyladenosine (m6A) modification is abnormally expressed in inflammatory bowel disease (IBD). This review explores how m6A regulatory proteins impact IBD pathogenesis and suggests potential new treatments.
Area of Science:
- Gastroenterology
- Molecular Biology
- Immunology
Background:
- Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic intestinal inflammatory condition with increasing incidence.
- Pathogenesis involves genetics, gut microbiota, immunity, and environmental factors.
- N6-methyladenosine (m6A), the most abundant mRNA modification, is dysregulated in IBD patients.
Purpose of the Study:
- To elucidate the abnormal expression of m6A modification and regulatory proteins in IBD.
- To summarize the underlying mechanisms of m6A involvement in IBD.
- To reveal IBD pathogenesis and explore alternative therapeutic strategies.
Main Methods:
- Literature review focusing on m6A modification in IBD.
- Analysis of studies investigating m6A regulatory proteins (Writers, Erasers, Readers).
- Examination of m6A's role in immune cell population balance and mRNA expression.
Main Results:
- m6A regulatory proteins are implicated in IBD progression.
- Dysregulated m6A impacts immune cell balance and mRNA expression.
- Mechanisms linking m6A to IBD pathogenesis are complex and require further investigation.
Conclusions:
- Abnormal m6A expression and regulatory protein activity contribute to IBD.
- Understanding m6A mechanisms offers potential for novel IBD treatments.
- Further research is crucial to fully unravel m6A's role in IBD.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
01:29Inflammatory Bowel Disease IV: Pharmacological Management
528
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
528
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
499
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
01:29Drugs for Treatment of Ulcerative Colitis in IBD
463
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
463
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
644
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
644
01:30Inflammatory Bowel Disease II: Crohn's Disease
960
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
960